Navigation Links
Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
Date:11/29/2011

NEWARK, Del., Nov. 29, 2011 /PRNewswire-iReach/ --  Quantum Leap Innovations announced today the appointment of Michael A. Cusumano to their Board of Directors.  Michael Cusumano is the Sloan Management Review Distinguished Professor of Management at the Massachusetts Institute of Technology's Sloan School of Management, with a joint appointment in the MIT Engineering Systems Division. His seminal 2010 book, STAYING POWER, covers six enduring principles for managing strategy and innovation in an uncertain world.

(Photo:  http://photos.prnewswire.com/prnh/20111129/CG13879)

"We are honored to have someone of Dr. Cusamano's stature agree to join our board," said Quantum Leap founder and CEO Joseph Budner Elad. "His support validates our vision of Pattern Based Analytics and the importance of our technology in today's uncertain world."

"It is with great pleasure and excitement that I join the Quantum Leap board," says Dr. Cusumano. "I have known the principals in the company for many years and have closely followed the evolution of their work in data analysis.  The pattern-based analytics approach took years to develop. It significantly improves our ability to visualize and make sense of complex data sets and then apply these insights to a wide variety of business and other applications."

About Michael Cusumano:

Michael Cusumano specializes in strategy, product development, and entrepreneurship in the computer software industry, as well as automobiles and consumer electronics. He teaches courses on The Software Business and Digital Platforms as well as Strategic Management and Managing Technological Innovation and Entrepreneurship.

Professor Cusumano earned his B.A. degree from Princeton and his Ph.D. from Harvard.  He completed a pos
'/>"/>

SOURCE Quantum Leap Innovations
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
3. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
4. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
5. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
6. Michael J. Fox Foundation Awards Grant to Zymes LLC
7. Dr. Michael Hanley Joins Celtaxsys as CEO
8. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
9. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
10. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
11. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Pomerantz LLP is investigating claims on behalf of investors ... IPXL).  Such investors are advised to contact Robert ... ext. 237. The investigation concerns whether Impax ... Sections 10(b) and 20(a) of the Securities Exchange Act ... Impax Laboratories, Inc. (the "Company") issued a press release ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014 TransVac Solutions, the ... collection and transport solutions for hospitals, will be exhibiting ... Engineering (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 ... its technology for making hospitals cleaner, reducing infection risk ... the hospital’s life cycle. Staff will be available ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... present during the 11th Annual BIO CEO & Investor,Conference ... The presentation,will be webcast from the Waldorf-Astoria Hotel ... To access the presentation via the Web, please go ...
... Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) ... and year ended December 31, 2008. , ... to $31.2 million,compared with $19.3 million in the fourth quarter ... assay was $30.9 million in the fourth,quarter of 2008, an ...
... Feb. 3 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., ... has obtained CE Mark approval for its Neurostep(TM) ... system (CLS) used on peripheral nerves. CE Mark ... the Neurostep(TM) in any of the Member States ...
Cached Biology Technology:Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 2Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3
(Date:7/29/2014)... an easier method to create DNAprotein conjugates. The ... diagnosing diseases. , DNA linked to proteins ... can be used in diagnostic techniques, nanotechnology and ... with DNA can be used for purposes ... biological material. The method also provides easier access ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
(Date:7/29/2014)... to go and almost 2500 registered participants, the final ... The event, a joint venture between the Federation of ... for Biochemistry and Molecular Biology (SFBBM), will take place ... the Palais des Congrs in Paris, France. , The ... life sciences in Europe this year. It features more ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2
... fattening than others? What about the risks of bariatric ... (ASN) on December 5-7 for answers to these questions ... Nutrition Conference. The 3-day program delivers valuable ... satellite sessions, and networking opportunities. Credentialed media, science writers ...
...   The Bensalem Township Police Department , in conjunction with ... of DNA testing.  This pilot program known as " BodeHITS ... kind in the country for law enforcement. Bensalem ... with over 6,000 DNA profiles consisting of evidence and reference/individual ...
... , Nov. 19, 2013 Nelson Laboratories ( www.nelsonlabs.com ... (#321) during BIOMEDevice in San ... Thor Rollins, biocompatibility specialist. Those interested in a consultation ... http://photos.prnewswire.com/prnh/20120727/LA47745LOGO ) Rollins will also present, ...
Cached Biology News:Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose 2
Request Info...
... Universal Amplicon Detection Assay (ADA) ... the qualitative detection and quantitation ... in vitro nucleic acid amplification. ... to be used in diagnostic ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
... ready-to-use reagents for the isolation of genomic ... for the isolation of genomic DNA from ... for the isolation of genomic DNA from ... can be used for restriction endonuclease digestion ...
Biology Products: